Обзорная статья

Targeting cancer stem cell pathways for cancer therapy

Liqun YangCancer Center, Medical Research Institute, Southwest University, 400716, Chongqing, ChinaPengfei ShiCancer Center, Medical Research Institute, Southwest University, 400716, Chongqing, ChinaGaichao ZhaoCancer Center, Medical Research Institute, Southwest University, 400716, Chongqing, ChinaJie XuCancer Center, Medical Research Institute, Southwest University, 400716, Chongqing, ChinaWen PengCancer Center, Medical Research Institute, Southwest University, 400716, Chongqing, ChinaJiayi ZhangCancer Center, Medical Research Institute, Southwest University, 400716, Chongqing, ChinaGuanghui ZhangCancer Center, Medical Research Institute, Southwest University, 400716, Chongqing, ChinaXiaowen WangCancer Center, Medical Research Institute, Southwest University, 400716, Chongqing, ChinaZhen DongCancer Center, Medical Research Institute, Southwest University, 400716, Chongqing, ChinaFei ChenDepartment of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, 48201, USAHongjuan CuiCancer Center, Medical Research Institute, Southwest University, 400716, Chongqing, China. [email protected]

2020en

ABI

Аннотация

Since cancer stem cells (CSCs) were first identified in leukemia in 1994, they have been considered promising therapeutic targets for cancer therapy. These cells have self-renewal capacity and differentiation potential and contribute to multiple tumor malignancies, such as recurrence, metastasis, heterogeneity, multidrug resistance, and radiation resistance. The biological activities of CSCs are regulated by several pluripotent transcription factors, such as OCT4, Sox2, Nanog, KLF4, and MYC. In addition, many intracellular signaling pathways, such as Wnt, NF-κB (nuclear factor-κB), Notch, Hedgehog, JAK-STAT (Janus kinase/signal transducers and activators of transcription), PI3K/AKT/mTOR (phosphoinositide 3-kinase/AKT/mammalian target of rapamycin), TGF (transforming growth factor)/SMAD, and PPAR (peroxisome proliferator-activated receptor), as well as extracellular factors, such as vascular niches, hypoxia, tumor-associated macrophages, cancer-associated fibroblasts, cancer-associated mesenchymal stem cells, extracellular matrix, and exosomes, have been shown to be very important regulators of CSCs. Molecules, vaccines, antibodies, and CAR-T (chimeric antigen receptor T cell) cells have been developed to specifically target CSCs, and some of these factors are already undergoing clinical trials. This review summarizes the characterization and identification of CSCs, depicts major factors and pathways that regulate CSC development, and discusses potential targeted therapy for CSCs.

Перевод пока недоступен

Идентификаторы

DOI: 10.1038/s41392-020-0110-5

Цитирования и источники

Цитирований: 5Использованных источников: 0

Показатели — AkademScholar